Facebook
Twitter
LinkedIn

Newsletter

NCI Announces $10M for up to 10 New Awards
Facebook
Twitter
LinkedIn

BayBio member company Omniox secured the only Phase IIB SBIR award from the National Cancer Institute in 2012. Omniox is developing technology that enhances anti-tumor therapies and secured its second grant from NCI.

NCI has announced $10M for up to ten new awards in FY2013 for small businesses that seek additional funding to support the next stage of development of NIH-supported SBIR Phase II projects in the areas of cancer therapeutics, imaging technologies, interventional devices, or diagnostics and prognostics. This funding opportunity is open to current and recently expired NIH SBIR Phase II projects, including both Phase II grants and contracts.* The deadline to submit an application for FY2013 is March 6, 2013.

Additional information can be foundĀ here.